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As hard as it is to believe now, it was permis-
sible not long ago to sell a prescription drug
(in the USA) without providing evidence that
it worked; all that was needed was evidence it
was safe. Then, KefauvereHarris changed
everything. Acting largely in response to the
thalidomide tragedy, Estes Kefauver,
a senator from Tennessee, and representative
Oren Harris from Arkansas introduced the
amendment that now bears their names. The
amendment required convincing evidence of
efﬁcacy, as well as safety, before a drug could
be brought to market.
1 It was signed into law
by John F Kennedy on 10 October 1962.
The effect of KefauvereHarris on clinical
practice is unequivocal; its effect on the
shaping of clinical evidence has been less
obvious. Although it would be hard to prove
a strong causeeeffect relation between
enactmentoftheamendmentandemergence
of controlled trials as the evidentiary ‘gold
standard,’ the timing is right. Reports of
controlled trials that meet reasonable meth-
odological standards began to enter the
medical literature in 1948, but their numbers
were small until 1966djust a few years after
KefauvereHarrisdat which point their
numbers soared, increasing about ﬁvefold
over the next 14 years.
2 (The Cochrane
Collaboration, which has been a powerful
force in establishing the dominance of
controlled trial evidence, clearly did not play
aroleinthissurge,sinceitcameintoexistence
only in 1993.) The rapid rise in healthcare
spending in the 1960s and 1970s almost
certainly reinforced the need for hard
evidence of efﬁcacy to avoid wasting medical
resources. However, it is hard to avoid the
conclusion that after 1962, clinical research
went increasingly where the money was,
and the money was ﬂowing increasingly
from industry as it set about meeting the new
legislative requirement for strong experi-
mental evidence that its products actually
work.
Since biological and social heterogeneity
among trial participants interferes with the
detection of true causeeeffect relationships,
controlled trials are carefully designed to
minimise or eliminate heterogeneity’s
effects, primarily by aggregating the
outcomes from many participants rather than
drawing inferences from outcomes in indi-
vidual persons.
3 This intentional ‘heteroge-
neity blindness’ in controlled trials has
brought with it a progressive shift from
qualitative documentation of the concreted
meticulous narrative case reports and case
series describing illness in individual
patients, which had dominated the medical
literature for decadesdto quantitative
assessment of the abstractdsophisticated
statistical inferences about summary effect
size in average patients.
Determining effect sizes by merging
outcome data from groups of study partici-
pants obscures the reality that clinical inter-
ventions rarely work for everyone and under
all circumstances. In large part, clinicians are
unable to face that reality because they lack
information about the biological, experien-
tial and environmental sources of that
heterogeneity, and the impact of that
heterogeneity on clinical responses. When an
intervention known to be effective in study
populations fails to work in a particular
patient, clinicians therefore have little choice
but to move to alternative interventions on
the basis of pragmatic rules of thumb
(heuristics).
4 5
The shift in medical evidence from ﬁne-
grained narrative to sweeping statistical
inference calls to mind analogous shifts in
perspective that have followed certain other
landmark changes in information systems.
For example, when satellite cameras became
available, they aggregated billions of bits of
information from the earth’s surface into
images from space, which have created a new,
emergent reality about land use, oceans,
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The structure of improvement knowledgeclimate and human activity. Curiously, although those
satellite images have created a new gold standard of
evidence, we continue to value ground-level knowledge
very highly, in contrast with the disdain we exhibit
towards clinical evidence from case reports and case
series; in fact, we easily accept the idea that these two
levels of evidence about the physical world are comple-
mentary.
What will it take to bring the focus of clinical evidence
back down from the homogenised ‘outer space’ of
controlled trials to the ground level of individual patient
experience, with its inherent variability? Two powerful
forces could move us in that direction. First, the explo-
sion in molecular genetics has reawakened interest in
the possibility of ‘personalised medicine’ in which ther-
apies are tailored to the speciﬁc biological and clinical
circumstances of individual patients.
6 The implications
of building heterogeneity from genetic and other
sources formally into clinical decision-making are at least
as profound for the business model of the pharmaceu-
tical industry as they are for clinical research, not least
because such individuation would probably spell the end
of the era of ‘blockbuster’ drugs. Second, it is increas-
ingly clear that improving the performance of health-
care systems inherently involves social change. Since the
social structure of individual care systems is at least as
heterogeneous as the biology of individual patients, it is
rapidly becoming clear that anyone who works to change
the performance of healthcare systems ignores that
heterogeneity at their peril.
37The epistemological value
of case reports has in fact received increased scholarly
attention in recent years
8e10; moreover, twice as many
clinical case reports are published annually as rando-
mised clinical trials, and the numbers of both are
increasing at about the same rate
11ddistant rumblings
that suggest the forces of individuation may be poised to
modulate the homogenising inﬂuence of experimental
study methods.
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